Recent News

• 06.03.2026 - FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
• 05.22.2026 - FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
• 05.18.2026 - FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
• 05.11.2026 - FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
• 05.05.2026 - FibroBiologics CEO Issues Letter to Shareholders
• 05.04.2026 - FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
• 05.04.2026 - FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
• 04.30.2026 - FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

Recent Filings

• 05.06.2026 - 8-K Current report
• 05.06.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.05.2026 - 8-K Current report
• 05.05.2026 - DEF 14A Other definitive proxy statements
• 05.05.2026 - ARS Annual Report to Security Holders
• 05.05.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.04.2026 - 4 Statement of changes in beneficial ownership of securities